Exploring 3 Undervalued Small Caps In United States With Insider Buying

In This Article:

The United States market has shown robust performance recently, climbing 1.2% in the last week and surging 32% over the past year, with earnings anticipated to grow by 16% annually. In this environment, identifying stocks that are potentially undervalued and have insider buying can be an intriguing strategy for investors seeking opportunities in small-cap companies.

Top 10 Undervalued Small Caps With Insider Buying In The United States

Name

PE

PS

Discount to Fair Value

Value Rating

Columbus McKinnon

21.5x

1.0x

41.90%

★★★★★★

Hanover Bancorp

9.5x

2.2x

48.63%

★★★★★☆

Citizens & Northern

12.7x

2.8x

44.35%

★★★★☆☆

Franklin Financial Services

9.8x

1.9x

38.58%

★★★★☆☆

HighPeak Energy

12.2x

1.5x

34.09%

★★★★☆☆

German American Bancorp

13.8x

4.6x

48.19%

★★★☆☆☆

Community West Bancshares

18.7x

2.9x

42.25%

★★★☆☆☆

Delek US Holdings

NA

0.1x

-774.50%

★★★☆☆☆

National Vision Holdings

NA

0.4x

-33.48%

★★★☆☆☆

Industrial Logistics Properties Trust

NA

0.7x

-215.15%

★★★☆☆☆

Click here to see the full list of 55 stocks from our Undervalued US Small Caps With Insider Buying screener.

Let's take a closer look at a couple of our picks from the screened companies.

Phibro Animal Health

Simply Wall St Value Rating: ★★★★★☆

Overview: Phibro Animal Health is a company engaged in the development, manufacturing, and marketing of a broad range of animal health and mineral nutrition products, with a market capitalization of approximately $0.56 billion.

Operations: The company generates revenue primarily from Animal Health, Mineral Nutrition, and Performance Products segments. Over recent periods, the gross profit margin has shown a slight upward trend, reaching 30.82% as of June 2024. Operating expenses have increased to $254.27 million in the same period, impacting net income margins which have decreased to 0.24%.

PE: 383.7x

Phibro Animal Health, a small company in the U.S., recently presented at the Morgan Stanley Global Healthcare Conference, showcasing their growth strategy. For fiscal year 2025, they project net sales between US$1.04 billion and US$1.09 billion, driven by their Animal Health segment's continued expansion and recovery in other areas. Despite lower profit margins this year compared to last (0.2% vs 3.3%), insider confidence is evident with recent share purchases from August to September 2024, suggesting belief in future prospects despite current challenges with high-risk funding sources and debt coverage issues.

NasdaqGM:PAHC Share price vs Value as at Oct 2024
NasdaqGM:PAHC Share price vs Value as at Oct 2024

Reservoir Media

Simply Wall St Value Rating: ★★★☆☆☆